European editorial board member Aksel Siva (Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey) considers the major unmet needs in the treatment of progressive multiple sclerosis.
Speaker disclosure: Aksel Siva has received honoraria for educational presentations and consultation fees from Novartis, Sanofi-Genzyme, F. Hoffmann-La Roche, Biogen Idec/Gen Pharma of Turkey, Merck Serono and Teva; received travel and registration coverage for attending several national or international congresses or symposia from Merck Serono, Biogen Idec/Gen Pharma of Turkey, Genzyme and , F. Hoffmann-La Roche.
Filmed at the 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway, June 2019.
